RadNet Jumps 6.8% to $77.28 on $622.7M Record Quarter

RadNet Inc (NASDAQ: RDNT) reported second-quarter fiscal 2026 revenue of $622.7 million, up 25% year over year, with artificial intelligence revenue up 136% and record adjusted EBITDA; the shares closed at $77.28, up 6.76% on Aug. 10, 2026.

RadNet Inc (NASDAQ: RDNT) used its second-quarter fiscal 2026 earnings call to put a number on something the diagnostic imaging industry has been arguing about for years: whether software can be sold at scale alongside scans. Revenue for the quarter reached $622.7 million, a 25% increase, and the company said revenue attributable to its artificial intelligence business rose 136%. Adjusted EBITDA — earnings before interest, taxes, depreciation and amortization, adjusted for one-off items, and the measure imaging operators lean on because of their heavy equipment depreciation — set a record.

The market response was emphatic in a session that offered almost nothing elsewhere. RadNet shares closed at $77.28, up 6.76% from the prior close of $72.39, having traded between $69.81 and $78.86 on the day. That is a wide intraday band for a mid-cap healthcare services name and suggests genuine disagreement being resolved in real time rather than a drift higher on light volume.

A 6.8% move against three flat benchmarks

Context sharpens the size of the move. The S&P 500 tracker (SPY) closed at $773.03, down 0.03%. The Nasdaq 100 tracker (QQQ) finished at $720.87, down 0.30%. The Dow tracker (DIA) ended at $538.99, down 0.12%. All figures are as of the last trade at 20:00 GMT on Aug. 10, 2026, with the market since closed.

In other words, none of RadNet's gain can be attributed to a rising tide. Whatever repriced the stock came from the company's own disclosure. When a name adds nearly 7% on a day the three major benchmarks are effectively unchanged, the information is idiosyncratic — earnings, guidance, or a segment number that changed how investors model the business.

The low of the day, $69.81, sits below the prior close. That detail matters: at some point in the session the stock was down, and the recovery to $78.86 at the high implies the buying built through the day rather than gapping in at the open and holding. Reports of the call, including coverage from GuruFocus, framed the quarter around record revenue and AI-driven expansion in digital health.

The question the 25% headline does not answer

A 25% revenue increase at an outpatient imaging operator can be assembled two very different ways, and the distinction determines what the multiple should be. Organic growth — more scans through existing centers, better payer mix, a shift toward higher-priced modalities — carries incremental margin because the fixed cost of the building and the magnet is already paid for. Acquired growth adds revenue but also adds the acquired cost base, integration expense and, typically, debt or equity issuance.

RadNet has historically been a consolidator in a fragmented market, buying independent imaging centers and folding them into regional networks. The company attributed part of the quarter's strength to advanced imaging volumes — MRI, CT, PET and similar higher-reimbursement studies as distinct from routine X-ray and ultrasound. That is the organic lever, and it is the more valuable one. Investors reading the full disclosure should isolate how much of the 25% came from same-center volume and how much arrived with a purchase order attached, because the two deserve different valuations.

The advanced-imaging mix point is worth dwelling on. A single MRI slot generates far more revenue per hour than a screening mammogram, and the equipment is already installed. Shifting the case mix upward is one of the few ways a capital-intensive service business improves margin without new capital, which is precisely why record adjusted EBITDA and advanced imaging volumes appeared in the same set of remarks.

What 136% AI growth is and is not

The 136% increase in AI revenue is the number that will drive the narrative, and it deserves careful handling. Percentage growth of that magnitude usually indicates a small base. A segment can triple in a year and still be a rounding error against $622.7 million of total revenue. RadNet's digital health arm sells imaging software and algorithmic reading tools, both to its own centers and to third-party providers, and the third-party channel is the one that would justify a software valuation on part of the enterprise.

The 136% increase in AI revenue is the number that will drive the narrative, and it deserves careful handling.

Two things determine whether the AI line is a genuine re-rating event:

Absolute scale. Growth rates fade as the base grows. What matters is whether the segment is large enough to move consolidated margin within a reasonable horizon.
Segment profitability. Software sold externally at high gross margin is a different asset from software developed as an internal cost center and booked as intersegment revenue. Whether the AI business contributes positively to adjusted EBITDA, or is still funded by the imaging network, is the single most important unresolved question from this quarter.

Health systems buying diagnostic AI have moved slowly, constrained by regulatory clearance, radiologist workflow and reimbursement pathways that were not built for software. A vendor that also operates hundreds of its own imaging centers has an advantage here: it can deploy internally, demonstrate throughput gains, and take that evidence to outside buyers. That is a real structural edge, and it is the strategic logic investors were paying for on Aug. 10.

What to watch from here

The near-term checklist is short and concrete. First, the segment disclosure in the 10-Q: revenue and profitability for the digital health business broken out from imaging, plus how much of it is external versus intersegment. Second, the organic-versus-acquired split behind the 25%, which will tell investors whether the growth is repeatable without further deals. Third, capital structure — imaging expansion consumes cash, and a consolidator running a software build at the same time is funding two capital programs simultaneously.

Fourth, and least discussed, is reimbursement. Outpatient imaging rates are set largely by payer schedules the operator does not control, and a favorable mix shift toward advanced modalities is only durable if those modalities keep their pricing. That risk sits outside management's hands entirely.

For now the tape has given its verdict: a 6.76% single-day gain to $77.28 while the S&P 500, Nasdaq 100 and Dow trackers all finished marginally lower. The follow-through over the coming sessions — whether the stock holds above the prior close of $72.39 — will indicate whether the market treated this as a durable re-rating or a one-day reaction to a large percentage on a small base.

Key facts

RDNT last close: $77.28, +6.76% (Aug 10, 2026, 20:00 GMT)
Q2 FY2026 revenue: $622.7 million, up 25% year over year
AI revenue growth: +136%
Day range: $69.81–$78.86 (prev close $72.39)

Frequently asked questions

How much revenue did RadNet report for Q2 2026?

RadNet reported second-quarter fiscal 2026 revenue of $622.7 million, a 25% increase year over year. The company also said it achieved record adjusted EBITDA for the quarter and pointed to advanced imaging volumes — higher-reimbursement modalities such as MRI, CT and PET — as a key driver of the growth.

What happened to RDNT shares after the earnings call?

RadNet stock closed at $77.28 on Aug. 10, 2026, up 6.76% from the previous close of $72.39. The shares traded in a wide band between $69.81 and $78.86 during the session, meaning the stock was below its prior close at one point before finishing sharply higher.

How fast is RadNet's AI business growing?

RadNet said revenue attributable to its artificial intelligence operations rose 136% in the quarter. Growth rates of that size typically indicate a small starting base, so the more important disclosures are the segment's absolute revenue and whether it contributes positively to consolidated adjusted EBITDA rather than being funded by the imaging network.

Is RadNet's AI segment profitable?

The material available from the earnings call confirms 136% AI revenue growth but does not establish segment-level profitability. Investors will need the segment breakout in the quarterly filing to see whether the digital health business contributes to earnings or is still a net investment supported by cash flow from the outpatient imaging centers.

How did RadNet's move compare with the broader market?

It stood out. On Aug. 10, 2026, the S&P 500 tracker closed at $773.03, down 0.03%; the Nasdaq 100 tracker at $720.87, down 0.30%; and the Dow tracker at $538.99, down 0.12%. With all three benchmarks slightly lower, RadNet's 6.76% gain was driven by company-specific news.

Why does organic versus acquired growth matter for RadNet?

Organic growth — more scans through existing centers or a shift to higher-priced studies — carries incremental margin because the buildings and equipment are already paid for. Acquired growth adds revenue along with the acquired cost base, integration expense and usually new debt or equity. The two justify different valuation multiples on the same headline growth rate.

Sources

RadNet Inc (RDNT) (Q2 2026) Earnings Call Highlights: Record Revenue and AI-Driven Growth ... — GuruFocus

Photo: MART PRODUCTION · Pexels Licence — source